Schrödinger — Third Quarter 2026 Earnings Summary

Schrödinger reported third-quarter 2026 total revenue of $64.5 million, a 19% increase year-over-year, driven by a 49% surge in hosted software revenue and a significant milestone payment from Structure Therapeutics. The company achieved an Annual Contract Value (ACV) of $44.7 million, representing 17% growth, and raised its full-year 2026 ACV guidance to a range of $222 million to $232 million. Drug discovery revenue reached $24.2 million, while the company maintained a net loss of $37.7 million for the quarter. Schrödinger also highlighted recent scientific publications in battery and materials science, alongside new therapeutic collaborations with Tectora Therapeutics and progress on its proprietary drug candidates.